Clinical Study On Acupoint Injection Of Astragalus Injection Combined With Interferon For Treating Chronic Hepatitis B Patients With Syndrome Of Liver Depression And Spleen Deficiency

Objective: To observe and evaluate the clinical efficacy of acupoint injection of astragalus injection combined with Peginterferon alpha 2a(Peg INFα-2a)for treating HBe Ag-positive chronic hepatitis B(CHB)patients with liver depression and spleen deficiency syndrome,to provide a reference for the treatment of HBe Ag-positive CHB patients with liver depression and spleen deficiency syndrome by combining traditional Chinese and western medicine.Methods: 60 cases of CHB patients with liver depression and spleen deficiency syndrome who were hospitalized at the Department of liver Diseases,Xiamen hospital of traditional Chinese medicine,Fujian,China,from December 2017 to June 2018,were randomly divided into control group and treatment group,30 cases in each group.The control group used Peg INFα-2a injection 180 μg/time,while the treatment group were treated by acupoint injection of astragalus injection combined with Peg INFα-2a.The treatment lasted 24 weeks.The clinical efficacy was observed by assessing the change of blood routine,liver function,HBs Ag level,HBe Ag negative conversion rate,HBV DNA negative conversion rate,TCM symptom scores and the incidence of main adverse reactions of interferon.The statistical analysis was used SPSS24.0 statistical software to compare the efficacy of the two groups.Results:(1)ALT normalization rate: At the end of treatment,the ALT normalization rate were much more in the treatment group(χ2=5.836,P=0.016),and the difference was statistically significant(P < 0.05).(2)HBs Ag levels: The compare within groups before and after treatment,comparison between the two groups after treatment were statistically significant(P < 0.05).And the compare within groups before and after treatment in control group was not statistically significant(P>0.05).(3)HBe Ag negative conversion rate and HBV DNA negative conversion rate: After treatment,the negative conversion rate of HBV DNA in the treatment group was superior to the control group(χ2=8.631,P=0.003),and the difference was statistically significant(P < 0.05).The negative conversion rate of HBe Ag between the two groups(χ2=2.248,P=0.134)was not statistically significant(P > 0.05).(4)TCM symptom scores: The comparison between the two groups after treatment,the scores of hypochondrium distending pain(Z=-2.165,P=0.03),tiredness and lack of power(Z=-2.326,P=0.02),belching and preference for sighing(Z=-2.085,P=0.037),thin sloppy stool(Z=-2.993,P=0.003)were statistically significant(P<0.05).(5)The main adverse reaction rate of interferon: a.Before and after treatment,compare within groups was statistically significant(P < 0.01).The comparison between the two groups after treatment was statistically significant(P < 0.05),and the NEUT and PLT decreased significantly in the treatment group compared with the control group;b.The incidence of fever(χ2=5.586,P=0.018),onset hypodynamia(χ2=5.695,P=0.017),loss of appetite(χ2=4.614,P=0.032),and insomnia(χ2=4.735,P=0.030)in the treatment group was lower than that in the control group at 6 months.Conclusion: Acupoint injection of astragalus injection can significantly enhance the immune regulation ability of HBe Ag-positive CHB patients with liver depression and spleen deficiency syndrome,reduce the adverse effects of interferon,improve the overall therapeutic effect,and achieve the advantage of "enhancing the effect and reducing the side effects" of integrated traditional Chinese and western medicine.